CA2989111C — Methods of using pyruvate kinase activators
Assigned to Agios Pharmaceuticals Inc · Expires 2023-10-03 · 3y expired
What this patent protects
ABSTRACT Described herein is Compound 1, N-(4-(4-(cyclopropylmethyl)piperazine- 1 -carbonyl)phenyl)quinoline-8-sulfonamide, or a pharmaceutically acceptable salt or hydrate thereof, for use in treatment of pyruvate kinase deficiency in …
USPTO Abstract
ABSTRACT Described herein is Compound 1, N-(4-(4-(cyclopropylmethyl)piperazine- 1 -carbonyl)phenyl)quinoline-8-sulfonamide, or a pharmaceutically acceptable salt or hydrate thereof, for use in treatment of pyruvate kinase deficiency in a subject in need thereof, for use in activation of pyruvate kinase in a subject in need thereof, for use in treatment of hemolytic anemia in a subject in need thereof, for use in treatment of thalassemia in a subject in need thereof, or for use in treatment of sickle cell anemia in a subject in need thereof. Compound 1 is for oral administration one or twice daily. Date Recue/Date Received 2022-12-20
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.